Abbott Laboratories

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Equities Analysts Offer Predictions for ABT FY2027 Earnings

AI-generated analysis

📈 Erste Group Bank raised its FY2027 EPS estimate for Abbott Laboratories to $6.06 per share.

📉 Bank of America reduced its price target from $120.00 to $102.00 in a recent research report.

🚀 JPMorgan Chase lifted its price target to $120.00 and reaffirmed an 'overweight' rating.

💰 Abbott Laboratories reported Q2 EPS of $1.31, beating the consensus estimate of $1.28.

📈 Revenue for the quarter reached $12.59 billion, representing a 13% year-over-year growth.

🎯 The company provided FY 2026 guidance with EPS targets between $5.45 and $5.60.

💸 A quarterly dividend of $0.63 per share was declared for payment on August 17th.

📊 Institutional investors own 75.18% of the company's outstanding shares.

🏦 J. Stern & Co. LLP increased its stake by over 12,400% in the fourth quarter.

🔍 The stock currently trades at a P/E ratio of 34.25 with a market cap of $183.12 billion.

Bullish Signals
  • Abbott Laboratories beat quarterly earnings expectations, reporting $1.31 EPS versus the consensus of $1.28.
  • The company achieved strong revenue growth of 13% year-over-year, reaching $12.59 billion for the quarter.
  • JPMorgan Chase upgraded its price target to $120 and maintained an 'overweight' rating on the stock.
  • Erste Group Bank increased its FY2027 EPS forecast to $6.06, signaling confidence in future performance.
  • Major institutional investors like J. Stern & Co., Norges Bank, and Arrowstreet Capital significantly increased their holdings.
  • The company maintains a consistent dividend policy with a 2.4% yield and an annualized payout of $2.52 per share.
Risk Factors
  • Bank of America lowered its price target from $120.00 to $102.00, indicating some analysts see limited upside.
  • Daiwa Securities downgraded the stock from 'outperform' to 'neutral' with a lower price target of $92.00.
Full Analysis
Equities analysts have issued mixed but generally positive signals regarding Abbott Laboratories (NYSE:ABT) ahead of its FY2027 earnings. Erste Group Bank lifted its full-year EPS estimate to $6.06, while JPMorgan Chase raised its price target to $120 and maintained an 'overweight' rating. Conversely, Bank of America cut its target to $102, and Daiwa Securities lowered its rating to neutral with a $92 target, reflecting varied market perspectives on the healthcare giant's valuation. The company recently reported strong quarterly results for the quarter ended July 16th, beating analyst expectations. Abbott Laboratories posted earnings per share of $1.31 compared to a consensus of $1.28, with revenue reaching $12.59 billion, a 13% year-over-year increase. The firm also provided forward guidance for Q3 2026 EPS between $1.38 and $1.46, and set full-year FY 2026 EPS targets ranging from $5.45 to $5.60. Abbott Laboratories continues to offer attractive income characteristics with a declared quarterly dividend of $0.63 per share, payable on August 17th to shareholders of record as of July 15th. This represents an annualized dividend yield of 2.4% and a payout ratio of 81.55%. Institutional ownership remains high at 75.18%, with significant recent position increases from major hedge funds like J. Stern & Co., Norges Bank, and Arrowstreet Capital.